These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8791109)

  • 1. Why chemoprevention?
    Hakama M
    IARC Sci Publ; 1996; (136):1-5. PubMed ID: 8791109
    [No Abstract]   [Full Text] [Related]  

  • 2. [The role of diet in the prevention of occupational cancer].
    Solenova LG; Smulevich VG
    Vopr Pitan; 1993; (4):36-40. PubMed ID: 8073692
    [No Abstract]   [Full Text] [Related]  

  • 3. Behavioural intervention versus chemoprevention.
    Henderson M; Thompson B; Kristal A
    IARC Sci Publ; 1996; (136):123-30. PubMed ID: 8791123
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer chemoprevention with dietary phytochemicals.
    Surh YJ
    Nat Rev Cancer; 2003 Oct; 3(10):768-80. PubMed ID: 14570043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemoprevention of cancer. Prevention of cancer in groups with increased risk].
    Sanner T; Dybing E
    Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2329-33. PubMed ID: 8804210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness considerations in chemoprevention of cancer.
    Habbema JD; van der Heide A; van den Bosch JM; Bonneux L
    IARC Sci Publ; 1996; (136):131-8. PubMed ID: 8791124
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of cancer: an ongoing saga.
    Kellen JA
    In Vivo; 1999; 13(5):423-6. PubMed ID: 10654197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer chemoprevention: a summary of the current evidence.
    Bonovas S; Tsantes A; Drosos T; Sitaras NM
    Anticancer Res; 2008; 28(3B):1857-66. PubMed ID: 18630472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention clinical trials: it is time to turn success into progress.
    Brown PH
    Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1531-2. PubMed ID: 17684123
    [No Abstract]   [Full Text] [Related]  

  • 11. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II.
    Moyad MA
    Urol Oncol; 2004; 22(6):472-7. PubMed ID: 15610864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I.
    Moyad MA
    Urol Oncol; 2004; 22(6):466-71. PubMed ID: 15610863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer chemoprevention: future holds in multiple agents.
    Mukhtar H; Ahmad N
    Toxicol Appl Pharmacol; 1999 Aug; 158(3):207-10. PubMed ID: 10438653
    [No Abstract]   [Full Text] [Related]  

  • 14. Ethical issues of intervention trials in cancer.
    Sancho-Garnier H; Joseph R
    IARC Sci Publ; 1996; (136):121-2. PubMed ID: 8791122
    [No Abstract]   [Full Text] [Related]  

  • 15. Signal transduction in cancer chemoprevention.
    Kong AN
    Mutat Res; 2004 Nov; 555(1-2):1-2. PubMed ID: 15476847
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer chemoprevention--an update on a (still) novel and exciting field of oncology.
    Gescher A; Steward WP
    Eur J Cancer; 2005 Sep; 41(13):1831-2. PubMed ID: 16051480
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ins and outs of dietary phytochemicals in cancer chemoprevention.
    Russo GL
    Biochem Pharmacol; 2007 Aug; 74(4):533-44. PubMed ID: 17382300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
    Armstrong WB; Taylor TH; Meyskens FL
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
    [No Abstract]   [Full Text] [Related]  

  • 20. Colon cancer: a USA viewpoint.
    Lipkin M
    IARC Sci Publ; 1996; (136):53-61. PubMed ID: 8791116
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.